{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:36:11Z","timestamp":1787783771691,"version":"build-2784847793"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.phrs.2016.02.014","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T11:28:05Z","timestamp":1455881285000},"page":"72-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics"],"prefix":"10.1016","volume":"106","author":[{"given":"Edoardo","family":"Spina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.02.014_bib0005","series-title":"Treatment of Epilepsy","first-page":"344","article-title":"Drug interactions","author":"Spina","year":"2015"},{"key":"10.1016\/j.phrs.2016.02.014_bib0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2016.02.014_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1528-1157.2002.043s2037.x","article-title":"Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs","volume":"43","author":"Spina","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.02.014_bib0020","series-title":"Stahl\u2019s Essential Psychopharmacology","first-page":"284","article-title":"Antidepressants","author":"Stahl","year":"2013"},{"key":"10.1016\/j.phrs.2016.02.014_bib0025","series-title":"Stahl\u2019s Essential Psychopharmacology","first-page":"129","article-title":"Antipsychotic agents","author":"Stahl","year":"2013"},{"key":"10.1016\/j.phrs.2016.02.014_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannesen Landmark","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2016.02.014_bib0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs: and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic. Disord."},{"key":"10.1016\/j.phrs.2016.02.014_bib0050","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with newer antiepileptic drugs (AEDs)-part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.02.014_bib0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with newer antiepileptic drugs (AEDs)-part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.02.014_bib0060","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2016.02.014_bib0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","article-title":"Clinically significant drug interactions with newer antidepressants","volume":"26","author":"Spina","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2016.02.014_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0075","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","article-title":"Clinically significant drug interactions with atypical antipsychotics","volume":"12","author":"Kennedy","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2016.02.014_bib0080","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00002826-200209000-00012","article-title":"Antiepileptic-antipsychotic drug interactions: a critical review of the evidence","volume":"25","author":"Mula","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200629020-00001","article-title":"Interactions between antiepileptic and antipsychotic drugs","volume":"29","author":"Besag","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2016.02.014_bib0090","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920008786049311","article-title":"Anticonvulsants-antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology","volume":"8","author":"Mula","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.phrs.2016.02.014_bib0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/17425255.2012.660918","article-title":"Interactions between antiepileptics and second-generation antipsychotics","volume":"8","author":"de Leon","year":"2012","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0100","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano","year":"2014","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0105","series-title":"Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-Glycoproteins","author":"Cozza","year":"2003"},{"key":"10.1016\/j.phrs.2016.02.014_bib0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/17425255.3.1.81","article-title":"Transporter-mediated drug interactions. Clinical implications and in vitro assessment","volume":"3","author":"Lin","year":"2007","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0115","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2016.02.014_bib0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1476-5381.2011.01557.x","article-title":"Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings","volume":"165","author":"O\u2019Brien","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0125","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second generation antipsychotics","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2016.02.014_bib0130","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40263-012-0008-z","article-title":"Psychotropic drug\u2013drug interactions involving P-glycoprotein","volume":"26","author":"Akamine","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2016.02.014_bib0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/epi.12100","article-title":"The treatment of depressive disorders in epilepsy: what all neurologists should know","volume":"54","author":"Kanner","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.02.014_bib0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yebeh.2013.03.029","article-title":"Treatments for patients with comorbid epilepsy and depression: a systematic literature review","volume":"28","author":"Mehndiratta","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.02.014_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bdi.12025","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013","volume":"15","author":"Yatham","year":"2013","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2016.02.014_bib0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","article-title":"Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment","volume":"27","author":"Rickels","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0155","first-page":"CD008943","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults","volume":"7","author":"Chaparro","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2016.02.014_bib0160","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S1474-4422(13)70193-5","article-title":"Combination pharmacotherapy for management of chronic pain: from bench to bedside","volume":"12","author":"Gilron","year":"2013","journal-title":"Lancet Neurol."},{"issue":"Suppl","key":"10.1016\/j.phrs.2016.02.014_bib0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0447.1989.tb07184.x","article-title":"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine","volume":"350","author":"Greb","year":"1989","journal-title":"Acta Psychiatry Scand."},{"key":"10.1016\/j.phrs.2016.02.014_bib0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-1211(91)90013-6","article-title":"No influence of the antidepressant paroxetine on carbamazepine valproate and phenytoin","volume":"10","author":"Andersen","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.phrs.2016.02.014_bib0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.v61n0712a","article-title":"Lack of sertraline efficacy probably due to an interaction with carbamazepine","volume":"61","author":"Kahn","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0180","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-001-0416-3","article-title":"Significant reduction of sertraline plasma levels by carbamazepine and phenytoin","volume":"57","author":"Pihlsgard","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0924-977X(02)00018-4","article-title":"Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study","volume":"12","author":"Steinacher","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2016.02.014_bib0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004850-199609004-00003","article-title":"Pharmacokinetics of milnacipran in comparison with other antidepressants","volume":"11","author":"Puozzo","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03190384","article-title":"Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects","volume":"26","author":"Sitsen","year":"2001","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.02.014_bib0200","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-002-0498-6","article-title":"Concomitant use of mirtazapine and phenytoin: a drug\u2013drug interactions study in healthy male subjects","volume":"58","author":"Spaans","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00004714-199510000-00004","article-title":"Carbamazepine but not valproate induces bupropion metabolism","volume":"15","author":"Ketter","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0210","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.jcp.0000270089.47533.b0","article-title":"Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers","volume":"27","author":"Helland","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JCP.0000000000000115","article-title":"False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: focus on bipolar disorder","volume":"34","author":"de Leon","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0220","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/YIC.0000000000000025","article-title":"Interaction of valproic acid and the antidepressants doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions","volume":"29","author":"Unterecker","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jnnp.55.5.412-a","article-title":"Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports","volume":"55","author":"Jalil","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1059-1311(05)80206-7","article-title":"Interaction between phenytoin and fluoxetine","volume":"3","author":"Darley","year":"1994","journal-title":"Seizure"},{"key":"10.1016\/j.phrs.2016.02.014_bib0235","first-page":"19","article-title":"Interaction of phenytoin and fluoxetine","volume":"107","author":"Woods","year":"1994","journal-title":"NZ Med. J."},{"key":"10.1016\/j.phrs.2016.02.014_bib0240","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00004714-199112000-00018","article-title":"A potential drug interaction between fluoxetine and valproic acid","volume":"11","author":"Sovner","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0245","first-page":"296","article-title":"Valproic acid toxicity with fluoxetine therapy","volume":"92","author":"Cruz-Flores","year":"1995","journal-title":"MO Med."},{"key":"10.1016\/j.phrs.2016.02.014_bib0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1176\/ajp.155.4.575","article-title":"Interaction of fluoxetine and valproic acid","volume":"155","author":"Lucena","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0255","first-page":"126","article-title":"Interaction of fluoxetine with carbamazepine","volume":"51","author":"Pearson","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/clpt.1991.98","article-title":"Increased carbamazepine plasma concentrations after fluoxetine coadmnistration","volume":"50","author":"Grimsley","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.02.014_bib0265","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00007691-199306000-00012","article-title":"Carbamazepine coadministration with fluoxetine or fluvoxamine","volume":"15","author":"Spina","year":"1993","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0270","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":"Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service","volume":"25","author":"Reimers","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0275","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1600-0447.1991.tb03200.x","article-title":"Interaction between carbamazepine and fluvoxamine","volume":"84","author":"Fritze","year":"1991","journal-title":"Acta Psychiatry Scand."},{"key":"10.1016\/j.phrs.2016.02.014_bib0280","first-page":"165","article-title":"Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?","volume":"47","author":"Bonnet","year":"1992","journal-title":"Therapie"},{"key":"10.1016\/j.phrs.2016.02.014_bib0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00007691-200102000-00014","article-title":"Phenytoin intoxication induced by fluvoxamine","volume":"23","author":"Mamiya","year":"2001","journal-title":"Ther. Drug Monit."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2016.02.014_bib0290","first-page":"20","article-title":"Absence of sertraline-mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine","volume":"57","author":"Rapeport","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2016.02.014_bib0295","first-page":"24","article-title":"Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin","volume":"57","author":"Rapeport","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0300","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/13651509909068397","article-title":"A sertraline\/valproic acid drug interaction","volume":"3","author":"Berigan","year":"1999","journal-title":"Int. J. Psychiatr. Clin. Pract."},{"key":"10.1016\/j.phrs.2016.02.014_bib0305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1059-1311(98)80074-5","article-title":"Lamotrigine toxicity secondary to sertraline","volume":"7","author":"Kaufman","year":"1998","journal-title":"Seizure"},{"key":"10.1016\/j.phrs.2016.02.014_bib0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0031-1297975","article-title":"Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study","volume":"45","author":"Christensen","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0315","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00004714-200110000-00007","article-title":"Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects","volume":"21","author":"Moller","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0320","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1055\/s-0031-1279730","article-title":"Probable interaction between trazodone and carbamazepine","volume":"44","author":"Sanchez-Romero","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0325","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/10401239509149035","article-title":"Bupropion and anticonvulsant drug interactions","volume":"7","author":"Popli","year":"1995","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0330","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1592\/phco.20.19.1448.34866","article-title":"Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects","volume":"20","author":"Odishaw","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2016.02.014_bib0335","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2007-979584","article-title":"Carbamazepine-induced changes in plasma levels of neuroleptics","volume":"28","author":"Tiihonen","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0345","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s002280050527","article-title":"A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanisms","volume":"54","author":"Lucas","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0350","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007691-199902000-00013","article-title":"Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication","volume":"21","author":"Olesen","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0355","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00007691-200208000-00009","article-title":"Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication","volume":"24","author":"Linnet","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0360","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting","volume":"24","author":"Skogh","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0365","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Progr. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0370","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0b013e3182693d2a","article-title":"Valproic acid significantly lowers serum concentrations of olanzapine. An interaction effect comparable with smoking","volume":"34","author":"Haslemo","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0375","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0380","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","article-title":"Quetiapine serum concentrations in psychiatric patients","volume":"26","author":"Hasselstrom","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0385","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1874241600801010017","article-title":"Therapeutic drug monitoring of quetiapine: effect of coadministration with antiepileptic drugs in patients with psychiatric disorders","volume":"1","author":"Santoro","year":"2008","journal-title":"Open Clin. Chem. J."},{"key":"10.1016\/j.phrs.2016.02.014_bib0395","first-page":"203","article-title":"Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice","volume":"31","author":"Wittman","year":"2010","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.phrs.2016.02.014_bib0400","first-page":"5","article-title":"Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine","volume":"32","author":"Nicki-Jockschat","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0405","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v58n1010b","article-title":"Risperidone and cytochrome P450 3A","volume":"58","author":"de Leon","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0410","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00004714-200102000-00020","article-title":"Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6","volume":"21","author":"Spina","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0415","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","article-title":"Plasma concentrations of risperidone and 9-hydroxy-risperidone effect of comedication with carbamazepine or valproate Ther","volume":"22","author":"Spina","year":"2000","journal-title":"Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0420","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00213-002-1056-8","article-title":"Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes","volume":"162","author":"Ono","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2016.02.014_bib0425","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0b013e3182966c2f","article-title":"Interaction between paliperidone and carbamazepine","volume":"35","author":"Yasui-Furukori","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpdd.122","article-title":"Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady state","volume":"3","author":"Kerbusch-Herben","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.phrs.2016.02.014_bib0435","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1046\/j.1365-2125.2000.00157.x","article-title":"The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0440","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/jcp.0b013e318056f309","article-title":"Pharmacokinetics of aripiprazole and concomitant carbamazepine","volume":"27","author":"Citrome","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0445","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0b013e3181b6326a","article-title":"Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia","volume":"31","author":"Nakamura","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0450","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-977715","article-title":"Effect of comedication on the serum level of aripiprazole: evidence from a routine therapeutic drug monitoring service","volume":"40","author":"Castberg","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0455","first-page":"23","article-title":"Effect of phenytoin on plasma clozapine concentrations in two patients","volume":"52","author":"Miller","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0460","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4088\/JCP.v59n0308b","article-title":"Elevated plasma clozapine concentrations after phenobarbital discontinuation","volume":"59","author":"Lane","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0465","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00007691-199812000-00008","article-title":"Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia","volume":"20","author":"Facciol\u00e0","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-200102000-00016","article-title":"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine","volume":"21","author":"Wong","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0475","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","article-title":"Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate","volume":"151","author":"Centorrino","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0480","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","article-title":"Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders","volume":"21","author":"Facciol\u00e0","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0485","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2005.10.008","article-title":"Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients","volume":"30","author":"Wong","year":"2006","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0490","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","article-title":"Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia","volume":"28","author":"Rajkumar","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0495","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0006-3223(94)90647-5","article-title":"Potential impact of valproic acid therapy on clozapine disposition","volume":"36","author":"Finley","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0500","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0505","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371866","article-title":"Can valproic acid be an inducer of clozapine metabolism","volume":"47","author":"Diaz","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0510","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0091217415621269","article-title":"Clozapine-induced myocarditis may be associated with rapid titration: a case report verified with autopsy","volume":"51","author":"Chopra","year":"2016","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.phrs.2016.02.014_bib0520","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0525","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.jcp.0000227353.46450.52","article-title":"Valproate lowers plasma concentration of olanzapine","volume":"26","author":"Bergemann","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0530","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FTD.0b013e3181c0590e","article-title":"Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder","volume":"31","author":"Spina","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0535","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","article-title":"Influence of age gender, body weight and valproate co-medication on quetiapine plasma concentrations","volume":"21","author":"Aichhorn","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0540","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hup.869","article-title":"Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia schizoaffective disorder, or bipolar disorder","volume":"22","author":"Winter","year":"2007","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.phrs.2016.02.014_bib0545","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00003088-200443110-00004","article-title":"Risperidone does not affect steady-state pharmacokinetics of divalproex sodium inpatients with bipolar disorder","volume":"43","author":"Ravindran","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.02.014_bib0550","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270004269870","article-title":"Pharmacokinetics of aripiprazole and concomitant lithium and valproate","volume":"45","author":"Citrome","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0555","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0091270011404028","article-title":"Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations","volume":"52","author":"Gerrits","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0560","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1176\/appi.ajp.158.11.1930","article-title":"Elevated clozapine plasma level with lamotrigine","volume":"158","author":"Kossen","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0565","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0006-3223(03)00524-9","article-title":"Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial","volume":"54","author":"Tiihonen","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0570","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.ftd.0000246763.59506.b0","article-title":"Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine: risperidone and olanzapine in patients with schizophrenia or bipolar disorder","volume":"28","author":"Spina","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0575","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1592\/phco.26.5.627","article-title":"Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers","volume":"26","author":"Jann","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2016.02.014_bib0580","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2125.2006.02598.x","article-title":"Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects","volume":"61","author":"Sidhu","year":"2006","journal-title":"Br. J Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0585","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2125.2011.03941.x","article-title":"Possible drug-druginteraction between quetiapine and lamotrigine\u2013evidence from a Swedish TDM database","volume":"72","author":"Andersson","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0590","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1176\/appi.ajp.162.4.811-a","article-title":"Increase in risperidone plasma level with lamotrigine","volume":"162","author":"Bienentreu","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2016.02.014_bib0595","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/FTD.0b013e3181956726","article-title":"Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole","volume":"31","author":"Waade","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2016.02.014_bib0600","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1528-1167.2005.71104.x","article-title":"Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine","volume":"46","author":"Muscatello","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.02.014_bib0605","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/cap.2015.0117","article-title":"Serum quetiapine concentration changes with concomitant oxcarbazepine therapy in a boy with autism spectrum disorder","volume":"25","author":"McGrane","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0610","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.02.014_bib0615","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.wnf.0000240955.49315.65","article-title":"Effect of topiramate on plasma concentrations of clozapine olanzapine, risperidone, and quetiapine in patients with psychotic disorders","volume":"30","author":"Migliardi","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0620","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002826-200203000-00007","article-title":"Carbamazepine-risperidone interaction in patients with epilepsy","volume":"25","author":"Mula","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0625","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1592\/phco.22.16.1500.33697","article-title":"Elevation of carbamazepine-10:11-epoxide by quetiapine","volume":"22","author":"Fitzgerald","year":"2002","journal-title":"Pharmacother."},{"key":"10.1016\/j.phrs.2016.02.014_bib0630","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2710.2012.01331.x","article-title":"Lack of a pharmacokinetic drug\u2013drug interaction between lithium andvalproate when co-administered with aripiprazole","volume":"37","author":"Boulton","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2016.02.014_bib0635","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":"Drug interaction between lamotrigine and psychoactive drugs","volume":"25","author":"Reimers","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2016.02.014_bib0640","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hup.999","article-title":"A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder","volume":"24","author":"Schieber","year":"2009","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.phrs.2016.02.014_bib0645","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/JCP.0b013e3181a497f1","article-title":"Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity use of repeated dosing, and translation into a message understandable to practicing clinicians","volume":"29","author":"de Leon","year":"2009","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181600044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181600044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T15:58:20Z","timestamp":1654358300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181600044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":129,"alternative-id":["S104366181600044X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.02.014","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}